T2 Biosystems Highlights Current and Future Opportunities for its Breakthrough Rapid Diagnostic Technology for Biothreat Pathogen Detection
Data on T2Candida auris research-use-only demonstrates 5-hour time-to-result
versus 14-days with blood culture
T2MR Technology demonstrates high sensitivity for the detection of biothreat pathogens
The presentation, A Rapid, Direct-from-Blood Diagnostic to Address Infections from Multidrug Resistant Organisms (MDROs), will take place on
During the presentation, Dr. Lowery will share a number of updates on the clinical utility of T2 technology that further prove T2MR’s ability to enable high-sensitivity, blood culture-independent detection of pathogens at ultra-high sensitivity, including:
- T2Bacteria provides actionable clinical information: New independent
T2Bacteria Panelclinical data demonstrates its ability to substantially benefit patients suspected of sepsis in both the emergency department and intensive care unit by providing information that enables significant reductions in time to effective therapy, de-escalation of unnecessary therapy, and avoidance of premature discharges and readmissions to the emergency department.
- T2Candida auris research-use-only provides significantly faster results in detecting the recently emerging superbug, Candida auris: Research data shows that the T2Candida auris
RUO Panelcan detect all four known clades of Candida auris in 5 hours, compared to 14 days with culture methods.
- T2Lyme clinical performance: T2Lyme clinical accuracy data show T2Lyme has higher accuracy than any of the currently available methods and higher positivity rate than existing PCR methods.
- T2MR Technology can detect five biothreat pathogens: New data show that the T2MR technology can detect five biothreat pathogens, including: Bacillus anthracis (anthrax), Burkholderia spp.,Rickettsia prowazekii, Francisella tularensis and Yersinia pestis. These biothreat pathogens can be detected by T2MR technology, which has been proven to work in whole blood (no pre-culture required), environmental samples, other biofluids, and swab samples.
The Department of Homeland Security(DHS) has defined these as biothreat pathogens because they require quick antibiotic treatment and can be difficult to diagnose due to non-distinguishing symptoms, making the development and availability of rapid, high-throughput, high sensitivity diagnostics for these biothreat pathogens a national priority.
“Like so many of our peers at this year’s Biodefense World Summit, we are increasingly concerned by the serious public health threat posed by MDROs on a global scale,” said
About T2 Biosystems
Gina Kent, Vault Communications
Source: T2 Biosystems, Inc.